GCG and overnutrition: Some primarily target systemic metabolic dysregulation driven by chronic overnutrition, including incretin analogs, such as glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide) and fibroblast growth factor-21 (FGF-21) receptor agonists (e.g., efruxifermin) [11,12].